Gilead Sciences, Inc. · NASDAQ:GILD
Gilead Sciences — J.P. Morgan Healthcare Conference 2024
24 slides from Gilead Sciences's conference presentation, Jan 8, 2024
Slide 1: 2024: A Year of Clinical Catalysts
2024: A Year of Clinical Catalysts J . P. M o r g a n H e a l t h c a r e C o n f e r e n c e 8 January 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and un
Slide 3: Meaningful Progress on Strategic Transformation
Meaningful Progress on Strategic Transformation Strong 2023 Execution Accelerating Oncology Leading HIV Portfolio → Catalyst Rich 2024 Business >$3B/Year Poised for Durable Growth 3
Slide 4: Meaningful Progress on Strategic Transformation
Meaningful Progress on Strategic Transformation Strong 2023 Execution Accelerating Oncology Leading HIV Portfolio Poised → Catalyst Rich 2024 Business >$3B/Year for Durable Growth • Returned base business to growth • Strong commercial performance • 5 potential new HIV product launches and clinical m
Slide 5: Transformation Taking Shape as Momentum Builds
Transformation Taking Shape as Momentum Builds Clear Portfolio Diversification Pipeline Positioned to Deliver Oncology On-Track to with 88% Growth in Pipeline 10+ New Transformative Contribute ~1/3 of Sales since 20191 Therapies by end of 2030 by end of 2030 ~33% Virology Inflammation 17 Oncology 5
Slide 6: Base Business Returned to Consistent Growth
Base Business Returned to Consistent Growth Net Product Revenue Trend Base Business Growth Offset Veklury Variability in 2022 and 2023 Veklury +7% to 8% YoY • Delivered 8 consecutive quarters of base business YoY growth in Q323 $24.8B – Base $22.1B $21.5B $21.4B $23.1B $25.0B1 Business • Base busine
Slide 7: Clinical Pipeline Full of Catalysts in 2024
Clinical Pipeline Full of Catalysts in 2024 Trodelvy EVOKE-01 in 2L+ mNSCLC Lenacapavir (Q6M SubQ) PURPOSE-1 for HIV PrEP 5+ Phase 3 Updates Trodelvy TROPiCS-04 in 2L+ mUC Trodelvy ASCENT-03 in 1L mTNBC (PD-L1-) Obeldesivir OAKTREE in COVID-19 standard-risk BIC/LEN (QD oral) Ph2 ARTISTRY-1; Ph3 FPI
Slide 8: … And Well Positioned in 2025 and Beyond
… And Well Positioned in 2025 and Beyond Healthy and Growing Pipeline of Earlier Stage Clinical & Pre-Clinical Programs1 Compared to Q1 2019 >180% 17 Phase 3 >55% 27 Phase 2 >35% 36 Phase 1 & Pre-IND >20% 78 Research Programs 8 1. Reflects 60 clinical programs and 20 pre-IND programs as of December
Slide 9: Meaningful Progress on Strategic Transformation
Meaningful Progress on Strategic Transformation Strong 2023 Execution Accelerating Oncology Leading HIV Portfolio Poised → Catalyst Rich 2024 Business >$3B/Year for Durable Growth • Returned base business to growth • Strong commercial performance • 5 potential new HIV product launches and clinical m
Slide 10: Strong Momentum as Oncology Exceeds $3B Run-Rate
Strong Momentum as Oncology Exceeds $3B Run-Rate Oncology Revenue Growth by Year ~12% of total • ~40% YoY growth for FY23 revenue • 6,000+ Oncology headcount ~$3B1 • 8 approved indications2 • Approvals in ~50 countries $2.14B 2% of $1.25B total revenue $656M $456M FY19 FY20 FY21 FY22 FY23 1. Based o
Slide 11: Trodelvy Programs Reinforce Pan-Tumor Potential
Trodelvy Programs Reinforce Pan-Tumor Potential Solid Tumors1 Triple-Negative Urothelial Breast Cancer Cancer 3 3 HR+ / HER2- Non-Small Cell Years on-market as the only Approved indications Breast Cancer Lung Cancer approved TROP2 ADC across 3 tumor types Endometrial Head and Cancer Neck Cancer >30K
Slide 12: Trodelvy: Expanding Potential to Reach More Patients
Trodelvy: Expanding Potential to Reach More Patients Indication Advancing into Earlier Lines 2L+ mTNBC ASCENT-03 1L mTNBC (PD-L1-)1 ~40K Addressable patients by 2030 Expanding Approvals Globally 2L+ mUC TROPiCS-04 2L+ mUC ~25K Addressable patients by 2030 ~120K Extending Potential 2L+ mNSCLC2 EVOKE-
Slide 13: Promising Clinical Activity for Trodelvy in 1L mNSCLC
Promising Clinical Activity for Trodelvy in 1L mNSCLC Cohort A (PD-L1 TPS≥50%) 100 Best overall response Percent change from baseline – target lesions 80 Partial response (n = 18) Stable disease (n = 7) • In the Phase 2 EVOKE-02 trial, Trodelvy plus 60 Progressive disease (n = 3) Last assessment bef
Slide 14: Trodelvy & Domvanalimab at Center of NSCLC Strategy
Trodelvy & Domvanalimab at Center of NSCLC Strategy 2023 2024 Updates Phase 3 EVOKE-01 Phase 3 EVOKE-03 Phase 3 STAR-121 Phase 2 ARC-7 T T D Z Phase 2 EVOKE-02 Phase 3 ARC-10 Phase 3 STAR-131 Phase 2 EVOKE-02 Cohorts A&B T Z D Z → D Z D Phase 2 VELOCITY Lung Phase 3 PACIFIC-8 Phase 2 VELOCITY Lung D
Slide 15: Building on Cell Therapy Leadership
Building on Cell Therapy Leadership Most extensive, long-term CAR T data available across multiple tumor types and lines of therapy • Yescarta is the #1 cell therapy in 2L+ LBCL and the only CAR T with: • FDA approved OS data in 2L LBCL • Long-term, 5-year OS of 43% in 3L LBCL Fastest and most relia
Slide 16: Potential Best-in-Class CAR T in Multiple Myeloma
Potential Best-in-Class CAR T in Multiple Myeloma Anito-cel: Differentiated Binding Domain • Robust Phase 1 data supports potential as best-in-class BCMA CAR T • 100% ORR, mPFS not reached at 26.5 months median follow-up 100% • 92% 6-month PFS rate and 76% 12-month PFS rate • Manageable safety profi
Slide 17: Comprehensive Pipeline with Combination Potential
Comprehensive Pipeline with Combination Potential Validated Targets Next-Generation Targets Examples of Phase 1 Programs CD19/20 CAR T: KITE-363 PARP1 EGFR / IL13Ra2 IL-18BP • DLBCL study ongoing TROP2 CAR T DGKα Inhibitor: GS-9911 GPC-2 TIGIT • Solid tumor study ongoing PD-1 CAR T • Potential combi
Slide 18: Meaningful Progress on Strategic Transformation
Meaningful Progress on Strategic Transformation Strong 2023 Execution Accelerating Oncology Leading HIV Portfolio Poised → Catalyst Rich 2024 Business >$3B/Year for Durable Growth • Returned base business to growth • Strong commercial performance • 5 potential new HIV product launches and clinical m
Slide 19: Biktarvy: Global Leader in HIV Treatment
Biktarvy: Global Leader in HIV Treatment More Than 1 Million People Are Managing Their #1 HIV with Biktarvy1 U.S. Naïve & New Starts G9 New Starts ~$12B2 $10.4B >47% ç $7.3B $8.6B U.S. Market Share in Q323 st 21 Consecutive Quarter of Growth $4.7B 2033 Projected U.S. and EU LOE $1.2B 2018 2019 2020
Slide 20: Industry Leading HIV Development Portfolio
Industry Leading HIV Development Portfolio Pre-IND Phase 1 Phase 2 Phase 3 GS-1219 (INSTI) GS-1720 (INSTI) Lenacapavir + Lenacapavir2 Lenacapavir Q6M INJECTION Islatravir (NRTTI) WEEKLY ORAL Q6M INJECTION Treatment WEEKLY ORAL Treatment Prevention Update in 1H24 Treatment Update in 1H24 PURPOSE-1 Up
Slide 21: Potential New Launches by 2030 in Treatment & PrEP
5 Potential New Launches by 2030 in Treatment & PrEP New Disclosure 2023 2024 PrEP Ph3 PURPOSE-1/-2 Fully Enrolled Ph2 PURPOSE-5 FPI 1H24 Long-Acting Twice-Yearly PrEP Q6M SubQ Lenacapavir for PrEP Ph2 PURPOSE-3/-4 FPI’d Ph3 PURPOSE-1 Update 2H24 Launch in Late-2025 Ph2 ARTISTRY-1 Update 1H24 Once-D
Slide 22: Clinical Pipeline Full of Catalysts in 2024
Clinical Pipeline Full of Catalysts in 2024 Trodelvy EVOKE-01 in 2L+ mNSCLC Lenacapavir (Q6M SubQ) PURPOSE-1 for HIV PrEP 5+ Phase 3 Updates Trodelvy TROPiCS-04 in 2L+ mUC Trodelvy ASCENT-03 in 1L mTNBC (PD-L1-) Obeldesivir OAKTREE in COVID-19 standard-risk BIC/LEN (QD oral) Ph2 ARTISTRY-1; Ph3 FPI
Slide 23: Upcoming Investor Events
Upcoming Investor Events 6 Q4 & FY Results FEB Tuesday, 6 February 2024 Kite Cell Therapy Event 1H Kite Manufacturing Facility HIV Event 2H Gilead HQ in Foster City, CA 23
Slide 24: 2024: A Year of Clinical Catalysts
2024: A Year of Clinical Catalysts J . P. M o r g a n H e a l t h c a r e C o n f e r e n c e 8 January 2024
Gilead Sciences — J.P. Morgan Healthcare Conference 2024 on 6ix